» Articles » PMID: 34924820

Implication of ARID1A Undercurrents and PDL1, TP53 Overexpression in Advanced Gastric Cancer

Overview
Specialty Oncology
Date 2021 Dec 20
PMID 34924820
Citations 2
Authors
Affiliations
Soon will be listed here.
Abstract

AT-rich interactive domain-containing protein 1A (ARID1A), TP53 and programmed cell death-ligand 1 (PDL1) are involved in several protein interactions that regulate the expression of various cancer-related genes involved in the progression of the cell cycle, cell proliferation, DNA repair, and apoptosis. In addition, gene expression analysis identified some common downstream targets of ARID1A and TP53. It has been established that tumors formed by -deficient cancer cells exhibited elevated expression. However, the aberrations in these molecules have not been studied in this population especially in Gastric Cancer (GC). In this backdrop we aimed to investigate the role of the mutation and expression of , and genes in the etiopathogenesis of Gastric Cancer (GC) in the ethnic Kashmiri population (North India). The study included 103 histologically confirmed GC cases. The mutations, if any, in exon-9 of gene was analysed by Polymerase Chain Reaction (PCR) followed by Sanger sequencing. The mRNA expression of the , and genes was analysed by Quantitative real time-PCR (qRT-PCR). We identified a nonsense mutation (c.3219; C > T) in exon-9 among two GC patients (∼2.0%), which introduces a premature stop codon at protein position 1073. The mRNA expression of the and gene was significantly reduced in 25.3% and elevated in 47.6 and 39.8% of GC cases respectively with a mean fold change of 0.63, 2.93 and 2.43. The data revealed that reduced mRNA expression of and elevated mRNA expression of and was significantly associated with the high-grade and advanced stage of cancer. Our study proposes that under-expression and overexpression of and might be crucial for tumor progression with and acting synergistically.

Citing Articles

Potential Regulation of by miR-129-5p and miR-3613-3p and Their Prognostic Value in Gastric Cancer.

Bure I, Vetchinkina E, Kalinkin A, Kuznetsova E, Molchanov A, Kiseleva A Int J Mol Sci. 2025; 26(1.

PMID: 39796161 PMC: 11719569. DOI: 10.3390/ijms26010305.


Mutations in Gastric Cancer: A Review with Focus on Clinicopathological Features, Molecular Background and Diagnostic Interpretation.

Angelico G, Attanasio G, Colarossi L, Colarossi C, Montalbano M, Aiello E Cancers (Basel). 2024; 16(11).

PMID: 38893181 PMC: 11171396. DOI: 10.3390/cancers16112062.


Identification of Potential Genomic Alterations Using Pan-Cancer Cell-Free DNA Next-Generation Sequencing in Patients With Gastric Cancer.

Kim B, Kim Y, Cho J, Lee K Ann Lab Med. 2023; 44(2):164-173.

PMID: 37903652 PMC: 10628753. DOI: 10.3343/alm.2023.0187.

References
1.
Hanahan D, Weinberg R . Hallmarks of cancer: the next generation. Cell. 2011; 144(5):646-74. DOI: 10.1016/j.cell.2011.02.013. View

2.
Chen X, Cao X, Kang A, Wang K, Su B, Wang Y . In situ expression and significance of B7 costimulatory molecules within tissues of human gastric carcinoma. World J Gastroenterol. 2003; 9(6):1370-3. PMC: 4611819. DOI: 10.3748/wjg.v9.i6.1370. View

3.
Sun J, Xu K, Wu C, Wang Y, Hu Y, Zhu Y . PD-L1 expression analysis in gastric carcinoma tissue and blocking of tumor-associated PD-L1 signaling by two functional monoclonal antibodies. Tissue Antigens. 2007; 69(1):19-27. DOI: 10.1111/j.1399-0039.2006.00701.x. View

4.
Ogawa M, Onoda N, Maeda K, Kato Y, Nakata B, Kang S . A combination analysis of p53 and p21 in gastric carcinoma as a strong indicator for prognosis. Int J Mol Med. 2001; 7(5):479-83. DOI: 10.3892/ijmm.7.5.479. View

5.
Olivier M, Hollstein M, Hainaut P . TP53 mutations in human cancers: origins, consequences, and clinical use. Cold Spring Harb Perspect Biol. 2010; 2(1):a001008. PMC: 2827900. DOI: 10.1101/cshperspect.a001008. View